Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 11,300 shares, a drop of 19.9% from the February 13th total of 14,100 shares. Based on an average daily volume of 38,300 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the shares of the stock are short sold.

Barinthus Biotherapeutics Trading Down 1.9 %

Shares of NASDAQ:BRNS opened at $1.04 on Tuesday. The business has a 50-day moving average price of $1.02 and a 200 day moving average price of $1.13. The company has a market capitalization of $41.84 million, a price-to-earnings ratio of -0.70 and a beta of -0.80. Barinthus Biotherapeutics has a 12-month low of $0.80 and a 12-month high of $4.16.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. acquired a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics accounts for 0.0% of Gilead Sciences Inc.’s holdings, making the stock its 14th biggest holding. Gilead Sciences Inc. owned 1.54% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price objective on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Monday, January 13th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.